Trevi Therapeutics Management
Management criteria checks 3/4
Trevi Therapeutics' CEO is Jennifer Good, appointed in Mar 2011, has a tenure of 15.5 years. total yearly compensation is $3.94M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $3.39M. The average tenure of the management team and the board of directors is 5.7 years and 9.4 years respectively.
Key information
Jennifer Good
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 15.78% |
| CEO tenure | 15.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.7yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
Seeking Alpha • Aug 20
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Summary Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout. With leading competitors exiting, TRVI's differentiated efficacy, reduced competition, and funded late-stage pipeline create a compelling risk/reward profile. Read the full article on Seeking Alpha
Narrative Update • Aug 15
TRVI: Chronic Cough Trials And Competitor Setbacks Will Support Rerating Potential
Analysts have raised their blended price target on Trevi Therapeutics to $28 from $26.18, citing expectations for smoother late-stage execution for Haduvio and a larger addressable opportunity following competitor setbacks in chronic cough. Analyst Commentary Recent research coverage around Trevi Therapeutics centers on how Haduvio might reshape expectations for chronic cough and related indications, and how that view feeds into valuation targets.Narrative Update • Aug 01
TRVI: Chronic Cough Franchise And Richer Margins May Support Rerating
Analysts have lifted their price target framework for Trevi Therapeutics, with the fair value estimate moving from about $24.90 to roughly $26.18 as they factor in higher assumed revenue growth, a slightly stronger profit margin, and continued support for Haduvio in idiopathic pulmonary fibrosis related chronic cough following recent research updates and competitor trial decisions. Analyst Commentary Recent Street research on Trevi Therapeutics centers on Haduvio's role in idiopathic pulmonary fibrosis related chronic cough and how competitive trial developments may affect the stock's risk and reward profile.Narrative Update • Jul 18
TRVI: Higher Long Term Profit Margin Assumptions Will Support A Richer Future Multiple
Trevi Therapeutics' analyst price target has been revised from $23.90 to $24.90. Analysts attribute this change to updated assumptions around long term profit margins and P/E expectations as key drivers of the revision.Narrative Update • Jun 26
TRVI: Equity Raise And Trial Milestones Will Support A Higher Future Multiple
Analysts have raised their price target on Trevi Therapeutics to $23.90 from $21.64, citing updated views on fair value and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research on Trevi Therapeutics highlights differing views on how the updated price targets align with the company’s execution risks and valuation assumptions.New Narrative • Mar 19
Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?Analysis Article • Apr 02
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Sep 19
Trevi adds 19% on full data set from mid-stage cough study
Clinical-stage biopharma, Trevi Therapeutics, Inc. (NASDAQ:TRVI) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CANAL study was designed to compare Haduvio, an oral extended-release formulation of pain therapy nalbuphine, against placebo in terms of the mean daytime cough frequency at Day 22 as the primary endpoint, as measured by an objective cough monitor. The full set of subjects (N=38) reached the primary endpoint with statistical significance indicating a 52.5% change in daytime cough frequency for Haduvio compared to placebo (p<0.0001). The reduction of cough frequency stood at ~76.1% and 25.3% in Haduvio and placebo arms, respectively. The safety profile was in line with data from previous studies for the treatment, and two adverse events were found to be unrelated to the experimental therapy. TRVI expects to start the next trial for this indication in H1 2023. A previous readout from 26 patients in the CANAL trial indicated a 52% placebo-adjusted reduction in daytime cough events for Haduvio.Seeking Alpha • Sep 11
Trevi Therapeutics: Moving Forward
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fibrosis. An investment analysis follows in the paragraphs below. "It's not unpatriotic to denounce an injustice committed on our behalf, perhaps it's the most patriotic thing we can do."― E.A. Bucchianeri Today, we take our first look at Trevi Therapeutics Inc. (TRVI). The small biopharma firm came public just over three years ago and is deep in Busted IPO territory even with a nice rebound in the shares so far in 2022. What lies ahead for Trevi Therapeutics? An analysis follows below. Seeking Alpha Company Overview Trevi Therapeutics is a clinical-stage biopharmaceutical company based out of New Haven, CT. The company focuses on the development of medicines to treat serious neurologically mediated conditions. Its primary asset in development is Haduvio which is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Haduvio has a dual mechanism of action by acting as both an antagonist (blocker) to the body's mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. March Company Presentation This candidate is currently being evaluating for the treatment of prurigo nodularis or PN and chronic cough in adults with idiopathic pulmonary fibrosis or IPF. Chronic cough represents a significant unmet need for IPF patients, as the majority of these patients report this cough as one of their most bothersome aspects of their disease. March Company Presentation Haduvio or Nalbuphine Extended Release [ER] has also been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. In 2011, Endo Pharmaceuticals partnered with Trevi to develop and market compounds incorporating nalbuphine hydrochloride. The stock currently trades just over three bucks a share and sports an approximate market capitalization of $140 million. Pipeline Developments Company Website The stock got a bump in late June 29th when the company disclosed that Haduvio had met key goals in a Phase 2b/3 'PRISM' study for patients with prurigo nodularis. 25% met the primary efficacy endpoint, a clinical measure called 4-point reduction in the Worst Itch - Numerical Rating Scale compared to just 14% of the placebo group. March Company Presentation Patients are currently completing the one-year open-label extension study, which should be over in January. The company is in the process of having an end of Phase 2 meeting with the FDA to discuss the data, next steps and the design for a registrational study that could lead to approval dependent on results. The company would like to do a six-month study with three treatment groups. March Company Presentation Four months before, interim data from a Phase 2 trial evaluating Haduvio to treat IPF suffering from chronic cough found a 52% placebo-adjusted reduction in daytime cough events and the compound was well tolerated. Full results should be out by the end of this quarter. A meeting with the FDA should happen to soon to move this effort to the next stage of development. The company believes this will begin in the first half of 2023. Haduvio could have other potential indications in this category (see above) for other indications. March Company Presentation Analyst Commentary & Balance Sheet Aegis Capital, Oppenheimer and Needham have all reiterated Buy ratings on TRVI over the past four months. All have identical $10 price targets on the stock.Analysis Article • Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$51m |
| Mar 31 2026 | n/a | n/a | -US$46m |
| Dec 31 2025 | US$4m | US$622k | -US$43m |
| Sep 30 2025 | n/a | n/a | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$47m |
| Mar 31 2025 | n/a | n/a | -US$47m |
| Dec 31 2024 | US$3m | US$608k | -US$48m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$597k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$898k | US$523k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$2m | US$506k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$1m | US$478k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$30m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$3m | US$435k | -US$27m |
Compensation vs Market: Jennifer's total compensation ($USD3.94M) is about average for companies of similar size in the US market ($USD5.22M).
Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.
CEO
Jennifer Good (61 yo)
15.5yrs
Tenure
US$3,944,892
Compensation
Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011 and had been its Interim Principal Financial Officer since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.5yrs | US$3.94m | 0.15% $ 3.4m | |
| Chief Development Officer | 2yrs | US$1.64m | 0% $ 0 | |
| Chief Commercial Officer | 6yrs | US$1.36m | 0.057% $ 1.3m | |
| Co-Founder & Chief Scientific Officer | 15.5yrs | US$977.13k | 0.16% $ 3.5m | |
| Chief Financial Officer & Principal Financial Officer | less than a year | no data | no data | |
| Controller & Chief Accounting Officer | 5.4yrs | no data | 0.018% $ 415.0k | |
| Communications Manager | no data | no data | no data |
5.7yrs
Average Tenure
65yo
Average Age
Experienced Management: TRVI's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.5yrs | US$3.94m | 0.15% $ 3.4m | |
| Independent Director | 7.9yrs | US$283.43k | 0.018% $ 413.2k | |
| Independent Director | 6.3yrs | US$275.93k | 0% $ 0 | |
| Independent Director | 9.2yrs | US$265.93k | 0% $ 0 | |
| Independent Chairman of the Board | 9.2yrs | US$293.43k | 0.25% $ 5.6m | |
| Independent Director | 9.6yrs | US$283.43k | 0.0045% $ 101.0k | |
| Member of Clinical Advisory Board | 13.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 13.5yrs | no data | no data |
9.4yrs
Average Tenure
64yo
Average Age
Experienced Board: TRVI's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 07:29 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trevi Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Conor MacKay | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |